Nel 2021 sono state pubblicate le raccomandazioni francesi per la […]
Search Results for: Trattamento della sindrome dell'intestino irritabile (IBS)
Here's what we've found for you
Nuova linea guida sulla prevenzione dello stroke (ictus)
Raccomandazioni cliniche aggiornate, tra cui cambiamenti nello stile di vita, […]
Morto Sammy Basso, aveva la sindrome dei 'nati vecchi'
La progeria, non altera la mente unico indice età del malato
Percorsi personalizzati contro il cancro legati al gene BRCA
Gli scienziati dell’Institute of Cancer Research hanno sviluppato un nuovo percorso […]
Multicohort study testing the generalisability of the SASKit-ML stroke and PDAC prognostic model pipeline to other chronic diseases
Objectives
To validate and test the generalisability of the SASKit-ML pipeline, a prepublished feature selection and machine learning pipeline for the prediction of health deterioration after a stroke or pancreatic adenocarcinoma event, by using it to identify biomarkers of health deterioration in chronic disease.
Design
This is a validation study using a predefined protocol applied to multiple publicly available datasets, including longitudinal data from cohorts with type 2 diabetes (T2D), inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and various cancers. The datasets were chosen to mimic as closely as possible the SASKit cohort, a prospective, longitudinal cohort study.
Data sources
Public data were used from the T2D (77 patients with potential pre-diabetes and 18 controls) and IBD (49 patients with IBD and 12 controls) branches of the Human Microbiome Project (HMP), RA Map (RA-MAP, 92 patients with RA, 22 controls) and The Cancer Genome Atlas (TCGA, 16 cancers).
Methods
Data integration steps were performed in accordance with the prepublished study protocol, generating features to predict disease outcomes using 10-fold cross-validated random survival forests.
Outcome measures
Health deterioration was assessed using disease-specific clinical markers and endpoints across different cohorts. In the HMP-T2D cohort, the worsening of glycated haemoglobin (HbA1c) levels (5.7% or more HbA1c in the blood), fasting plasma glucose (at least 100 mg/dL) and oral glucose tolerance test (at least 140) results were considered. For the HMP-IBD cohort, a worsening by at least 3 points of a disease-specific severity measure, the “Simple Clinical Colitis Activity Index” or “Harvey-Bradshaw Index” indicated an event. For the RA-MAP cohort, the outcome was defined as the worsening of the “Disease Activity Score 28” or “Simple Disease Activity Index” by at least five points, or the worsening of the “Health Assessment Questionnaire” score or an increase in the number of swollen/tender joints were evaluated. Finally, the outcome for all TCGA datasets was the progression-free interval.
Results
Models for the prediction of health deterioration in T2D, IBD, RA and 16 cancers were produced. The T2D (C-index of 0.633 and Integrated Brier Score (IBS) of 0.107) and the RA (C-index of 0.654 and IBS of 0.150) models were modestly predictive. The IBD model was uninformative. TCGA models tended towards modest predictive power.
Conclusions
The SASKit-ML pipeline produces informative and useful features with the power to predict health deterioration in a variety of diseases and cancers; however, this performance is disease-dependent.
La migliore soluzione per l’emicrania è rappresentata dai triptani
Per l’emicrania, i triptani, come eletriptan, rizatriptan, sumatriptan e zolmitriptan, sembrano […]
Fibrosi polmonare, Nerandomilast potenziale trattamento orale
Bene lo studio di fase III
Scambia, 'per il tumore di Bianca Balti ottime possibilità di trattamento'
‘In molti casi otteniamo la guarigione, ma la prevenzione è fondamentale’
Sorridere fa bene agli occhi, riduce secchezza come il collirio
Studio, utile per sindrome dell’occhio secco
ACG: linee guida sul trattamento dell’infezione da Helicobacter pylori
L’H.pylori è un batterio che infetta oltre la metà della […]
Al via sviluppo terapia genica fetale, farmaci per malattia rara
Sindrome di Leigh,progetto vincitore bando Multi-round Telethon
Quantitative sensory testing and chronic pain syndromes: a cross-sectional study from TwinsUK
Objective
The chronic pain syndromes (CPS) include syndromes such as chronic widespread pain (CWP), dry eye disease (DED) and irritable bowel syndrome (IBS). Highly prevalent and lacking pathognomonic biomarkers, the CPS are known to cluster in individuals in part due to their genetic overlap, but patient diagnosis can be difficult. The success of quantitative sensory testing (QST) and inflammatory biomarkers as phenotyping tools in conditions such as painful neuropathies warrant their investigation in CPS. We aimed to examine whether individual QST modalities and candidate inflammatory markers were associated with CWP, DED or IBS in a large, highly phenotyped population sample.
Design
Cross-sectional study.
Setting
Community-dwelling cohort.
Participants
Twins from the TwinsUK cohort
Primary and secondary outcome measures
We compared 10 QST modalities, measured in participants with and without a CWP diagnosis between 2007 and 2012. We investigated whether inflammatory markers measured by Olink were associated with CWP, including interleukin-6 (IL-6), IL-8, IL-10, monocyte chemoattractant protein-1 and tumour necrosis factor. All analyses were repeated in DED and IBS with correction for multiple testing.
Results
In N=3022 twins (95.8% women), no association was identified between individual QST modalities and CPS diagnoses (CWP, DED and IBS). Analyses of candidate inflammatory marker levels and CPS diagnoses in n=1368 twins also failed to meet statistical significance.
Conclusion
Our findings in a large population cohort suggest a lack of true association between singular QST modalities or candidate inflammatory markers and CPS.
Linee guida ESC 2024 per la prevenzione e il trattamento dell’ipertensione arteriosa
Questa linea guida della European Society of Cardiology (ESC) presentata a […]
Linee guida ESC 2024 per la sindrome coronarica cronica
Presentate a Londra durante il Congresso in corso della European Society […]
Linee guida ESC 2024 per la gestione della fibrillazione atriale
Le linee guida pratiche della Società Europea di Cardiologia (ESC) […]
Linee guida sull’identificazione e gestione dell’insufficienza surrenalica
Questa linea guida pubblicata da NICE riguarda l’identificazione e la gestione […]